| abstract |
The present invention provides a compound having the structure: or an enantiomer, specific tautomer, or pharmaceutically acceptable salt thereof, wherein R 1 is substituted or unsubstituted phenyl, or 1 A 5- or 6-membered heterocyclic or heteroaromatic ring containing from 5 to 5 heteroatoms, wherein R 2 is hydrogen, substituted or unsubstituted alkyl, —C (O) -alkyl, —C ( O) -O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, R 3 is hydrogen or substituted or unsubstituted alkyl, —C (O) -Alkyl, -C (O) -O-alkyl, alkoxy, cycloalkyl, alkenyl, mono- or bicyclic aryl, heteroaryl or heterocyclic moieties, or R 2 And R 3 combine to form a heterocyclic ring, where the dash line represents a second bond that may or may not be present, which is present when R 3 is oxygen, and R 4 and R 5 Each independently represents substituted or unsubstituted alkyl, —C (O) -alkyl, —C (O) —O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or A heterocyclic moiety, or a combination of the three of R 4 NR 5 , substituted or unsubstituted, monocyclic or bicyclic, containing 1 to 6 heteroatoms, or a heteroaryl moiety R 12 is hydrogen, alkyl, halogen, or cyano, and n is 0, 1, 2, 3 or 4, and said A by administering a therapeutically effective amount of a compound of the invention 2b Ade It provides a method for treating a thin receptor related disease. [Chemical 1] |